Table 1 Baseline characteristics of patients in training cohort and validation cohort
Patient characteristics | Training Cohort (N = 120) | Validation Cohort (N = 43) | P value |
|---|---|---|---|
Age (Median) | 61.21 | 60.35 | 0.582 |
Gender | |||
Male | 108 (90.0%) | 34 (79.1%) | 0.066 |
Female | 12 (10.0%) | 9 (20.9%) | |
Smoking history | |||
No | 57 (47.5%) | 25 (58.1%) | 0.231 |
Yes | 63 (52.5%) | 18 (41.9%) | |
Drinking history | |||
No | 72 (60.0%) | 23 (53.5%) | 0.457 |
Yes | 48 (40.0%) | 20 (46.5%) | |
T stage | |||
T1-T2 | 29 (24.2%) | 5 (11.6%) | 0.083 |
T3-T4 | 91 (75.8%) | 38 (88.4%) | |
N stage | |||
N0-N1 | 59 (49.2%) | 17 (39.5%) | 0.277 |
N2-N3 | 61 (50.8%) | 26 (60.5%) | |
Stage | |||
III | 31 (25.8%) | 13 (30.2%) | 0.577 |
IV | 89 (74.2%) | 30 (69.8%) | |
Lung metastasis | |||
No | 101 (84.2%) | 34 (79.1%) | 0.447 |
Yes | 19 (15.8%) | 9 (20.9%) | |
Brain metastasis | |||
No | 118 (98.3%) | 43 (100.0%) | > 0.999 |
Yes | 2 (1.7%) | 0 (0%) | |
Bone metastasis | |||
No | 110 (91.7%) | 41 (95.3%) | 0.734 |
Yes | 10 (8.3%) | 2 (4.7%) | |
Liver metastasis | |||
No | 104 (86.7%) | 38 (88.4%) | 0.775 |
Yes | 16 (13.3%) | 5 (11.6%) | |
Radiotherapy | |||
No | 32 (26.7%) | 12 (27.9%) | 0.875 |
Yes | 88 (73.3%) | 31 (72.1%) | |
Chemotherapy | |||
No | 23 (19.2%) | 12 (27.9%) | 0.231 |
Yes | 97 (80.8%) | 31 (72.1%) | |
PD-L1 | |||
< 57.5% | 26 (63.4%) | 34 (79.1%) | 0.112 |
≥ 57.5% | 15 (36.6%) | 9 (20.9%) | |
ESCC-PS | |||
ESCC-PS 1 | 32 (26.7%) | 19 (44.2%) | 0.071 |
ESCC-PS 2 | 57 (47.5%) | 13 (30.2%) | |
ESCC-PS 3 | 31 (25.8%) | 11 (25.6%) |